Boehringer Ingelheim’s lung disease drug nerandomilast has been successful in a Phase III study paving the way for the ...

The AI model works by examining each video frame to find important features of the lungs and assesses the order of the video ...

A Peninsula biotech company focusing on a deadly lung-scarring disease lost more than half its stock value Monday after ...

Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...

In what one analyst called a “unique situation,” the company stopped dosing patients on the recommendation of trial monitors, ...

Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in a related lung disease leading the drugmaker to expand the indications it ...

Pliant (PLRX) stock plunged 61% on news it has paused enrollment in a Phase 2b study of its drug bexotegrast in patients with ...

Topline data from FIBRONEER™-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change ...

The FDA has granted priority review to brensocatib to treat patients with non-cystic fibrosis bronchiectasis, according to a ...

It is unclear why an independent data safety monitoring board recommended the suspension of Pliant’s Phase IIb/III BEACON-IPF ...